###begin article-title 0
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 91 96 <span type="species:ncbi:9606">human</span>
Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 57 60 57 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 160 163 160 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 257 260 257 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID1</italic>
###xml 262 265 262 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID2</italic>
###xml 270 273 270 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID3</italic>
###xml 433 436 433 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID3</italic>
###xml 547 550 547 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 624 629 <span type="species:ncbi:9606">human</span>
Inhibitor of DNA binding/Inhibitor of differentiation 4 (ID4) is a critical factor for cell proliferation and differentiation in normal vertebrate development. ID4 has regulative functions for differentiation and growth of the developing brain. The role of ID1, ID2 and ID3 are expected to be oncogenic due to their overexpression in pancreatic cancer and colorectal adenocarcinomas, respectively. Aside from these findings, loss of ID3 expression was demonstrated in ovarian cancer. The aim of the present study was to reveal the factual role of ID4 in carcinogenesis in more detail, since its role for the pathogenesis of human breast cancer has been discussed controversially, assigning both oncogenic and tumour suppressive functions. 
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 26 29 26 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 311 314 311 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 525 528 525 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 555 558 555 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 568 571 568 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 734 737 734 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 98 103 <span type="species:ncbi:9606">human</span>
###xml 411 416 <span type="species:ncbi:9606">human</span>
ID4 promoter methylation, ID4 mRNA expression and ID4 protein expression were analysed in primary human breast cancer specimens using methylation-specific PCR (MSP) (n=170), semiquantitative realtime RT-PCR (n=46) and immunhistochemistry (n=3), respectively. In order to demonstrate a functional association of ID4 promoter methylation with its gene silencing, we performed DNA demethylation analysis with four human breast cell lines using MSP and semiquantitative realtime RT-PCR. In addition, we performed correlations of ID4 promoter methylation with ID4 mRNA and ID4 protein expression in matched samples of breast tumour and corresponding normal tissue. We carried out statistical analyses in order to find correlations between ID4 promoter methylation and clinicopathological parameters. 
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 9 12 9 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 181 184 181 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 351 354 351 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 400 403 400 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 471 474 471 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
Frequent ID4 promoter methylation was observed in primary breast cancer samples (69%, 117/170). We found a tight correlation (P<0.0001) between ID4 promoter methylation and loss of ID4 expression in primary breast cancer 3 specimens. Demethylating treatment with breast cancer cell lines was associated with clear ID4 mRNA re-expression. Tumours with ID4 promoter methylation showed distinct loss of ID4 expression on both transcription and protein level. Interestingly, ID4 promoter methylation was a factor for unfavourable recurrence-free survival (P=0.036) and increased risk for lymph node metastasis (P=0.030). 
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 185 188 185 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 249 254 <span type="species:ncbi:9606">human</span>
ID4 is indeed a novel tumour suppressor gene in normal human breast tissue and is epigenetically silenced during cancer development, indicating increased risk for tumour relapse. Thus, ID4 methylation status could serve as a prognostic biomarker in human breast cancer.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 494 514 494 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">retinoblastoma gene </italic>
###xml 643 644 643 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 764 768 764 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1024 1027 1024 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID1</italic>
###xml 1029 1033 1029 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID2 </italic>
###xml 1037 1041 1037 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID3 </italic>
###xml 1117 1118 1117 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1152 1153 1152 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1169 1173 1169 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID3 </italic>
###xml 1265 1266 1265 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1267 1268 1267 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1408 1409 1408 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1589 1590 1589 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1745 1748 1745 1748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 1748 1752 1748 1752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INKa</italic>
###xml 1748 1752 1748 1752 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INKa</italic></sup>
###xml 1754 1757 1754 1757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p15</italic>
###xml 1757 1760 1757 1760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 1761 1762 1761 1762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1757 1762 1757 1762 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>b</italic></sup>
###xml 1764 1767 1764 1767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14</italic>
###xml 1767 1770 1767 1770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARF</italic>
###xml 1767 1770 1767 1770 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ARF</italic></sup>
###xml 1772 1811 1772 1811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">death-associated protein kinase (DAPK) </italic>
###xml 1815 1862 1815 1862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O-6-methylguanine-DNA methyltransferase (MGMT) </italic>
###xml 1863 1865 1863 1865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1963 1968 1963 1968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 1970 1981 1970 1977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">14-3-3&#963;</italic>
###xml 1983 1992 1979 1988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIM3 ESR1</italic>
###xml 1994 1998 1990 1994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGR </italic>
###xml 2002 2013 1998 2009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E-cadherin </italic>
###xml 2014 2016 2010 2012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 2023 2027 2019 2023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 2171 2173 2167 2169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 2233 2237 2229 2233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 2323 2325 2319 2321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 2345 2347 2341 2343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 2370 2371 2366 2367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 2397 2401 2393 2397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 2580 2582 2576 2578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 2729 2735 2725 2731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 2736 2738 2732 2734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 2739 2741 2735 2737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 2754 2758 2750 2754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 2938 2940 2934 2936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 3352 3354 3348 3350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 3395 3399 3391 3395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 3513 3517 3509 3513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 3610 3612 3606 3608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 3664 3668 3660 3664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 3885 3894 3881 3890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 3923 3925 3919 3921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 3992 3996 3988 3992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 4033 4037 4029 4033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 4130 4134 4126 4130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 4167 4171 4163 4167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 4351 4355 4347 4351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 973 978 <span type="species:ncbi:9606">human</span>
###xml 1070 1075 <span type="species:ncbi:9606">human</span>
###xml 1393 1398 <span type="species:ncbi:9606">human</span>
###xml 2328 2333 <span type="species:ncbi:9606">human</span>
###xml 2377 2382 <span type="species:ncbi:9606">human</span>
###xml 2587 2592 <span type="species:ncbi:9606">human</span>
###xml 3026 3031 <span type="species:ncbi:9606">human</span>
###xml 3171 3176 <span type="species:ncbi:9606">human</span>
###xml 3241 3244 <span type="species:ncbi:10116">rat</span>
###xml 3692 3697 <span type="species:ncbi:9606">human</span>
###xml 3930 3935 <span type="species:ncbi:9606">human</span>
###xml 4210 4215 <span type="species:ncbi:9606">human</span>
###xml 4323 4330 <span type="species:ncbi:9606">patient</span>
ID4 is the most recently discovered member of the Inhibitor of DNA binding/Inhibitor of differentiation family of transcription factors. ID proteins contain a helix-loop-helix (HLH) domain enabling interaction with other basic helix-loop-helix (bHLH)-proteins. Via hetero-dimerisation with those transcription factors, ID proteins act as dominant negative inhibitors of gene transcription [1]. In addition, ID proteins can also bind to some important non-bHLH transcription factors such as the retinoblastoma gene product (RB1) or the paired box (PAX)-proteins, thereby regulating important pathways in cell proliferation and differentiation [2,3]. Furthermore ID4 was found to be an important factor for the development of the nervous system. In this tissue, the ID4 gene is highly expressed in migrating postmitotic neurons, in Purkinje cells, as well as in the adult cerebellum. Since ID proteins regulate fundamental cellular processes, a link of ID dysregulation with human carcinogenesis has been recently postulated. ID1, ID2 and ID3 are overexpressed in several human tumour entities, e.g. pancreatic cancer [4] and colorectal adenocarcinomas [5]. In addition, ID3 showed decreased expression levels in several tumour types such as ovarian adenocarcinomas [6,7]. In contrast to the putative oncogenic properties of ID1 and ID2, ID4 expression was found to be decreased in a variety of human cancers [8]. Recently, it has become very evident that aberrant epigenetic modifications such as promoter methylation play a decisive role in the dysregulation of gene expression in cancer [9]. Hypermethylation of CpG-rich regions (CpG islands) in promoter sequences is an important mechanism for the silencing of tumour suppressor genes such as p16INKa, p15INK4b, p14ARF, death-associated protein kinase (DAPK) and O-6-methylguanine-DNA methyltransferase (MGMT) [10]. In breast cancer, a variety of critical genes were shown to be inactivated by methylation e.g. BRCA1, 14-3-3sigma, TIM3 ESR1, PGR and E-cadherin [11]. The ID4 promoter region contains also CpG islands which were found to be hypermethylated in gastric adenocarcinomas in association with gene silencing [12]. Several studies reported a potential correlation between ID4 promoter methylation and tumour initiation/progression, e.g. in colorectal carcinoma [13], human leukaemia [14] and prostate cancer [2]. In human breast tissue ID4 mRNA was found to be constitutively expressed in normal mammary epithelial cells, but suppressed in oestrogen receptor (ER)-positive breast carcinomas and pre-neoplastic lesions [15]. A human ribozyme library-based inverse genomics approach revealed that ID4 may act as a negative regulator of the common tumour suppressor gene BRCA1 [16,17]. Moreover, ID4 expression levels were found to be decreased in BRCA1/ER-positive breast cancer specimens, suggesting that ID4 participates in molecular events regulating ER and BRCA1 expression [18]. Aside from these expression data, a role of ID4 as a putative tumour suppressor in human breast cancer development has been discussed controversially and is uncertain yet. In contrast to the common ID4 downregulation in several human tumour entities, one study detected increased ID4 expression in rat mammary gland cells in conjunction with increased weight, proliferation and invasiveness of these tumours [19]. However, another study suggested that ID4 may act as tumour suppressor gene in a fraction of primary breast cancers, since aberrant hypermethylation of the ID4 gene promoter in T1 tumours was associated with an increased risk for lymph node metastasis [20]. In the present study, we readdressed the role of ID4 promoter methylation in human breast cancer development. To that end we analysed a large cohort (n = 170) of cryoconserved samples of breast cancer specimens, including all tumour sizes and histological grades. Using in vitro DNA demethylation treatment [21] of human breast cancer cell lines we wanted to determine whether ID4 promoter hypermethylation may affect ID4 mRNA transcription. Our next aim was to demonstrate for the first time a correlation between ID4 promoter methylation and loss of ID4 mRNA and protein expression in primary human breast cancer specimens. Finally, we aimed to analyse statistical correlations between clinicopathological patient characteristics and ID4 methylation and expression data.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient samples
###end title 13
###begin p 14
###xml 835 836 835 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
###xml 801 808 <span type="species:ncbi:9606">patient</span>
Breast tissue samples (n = 170) used for methylation and mRNA expression analyses were obtained from patients treated by primary surgery for breast cancer at the Departments of Gynaecology at the University Hospitals of Aachen, Jena, Regensburg and Dusseldorf, Germany, with institutional review board approval. All patients gave informed consent to the study for retention and analysis of their tissue for research purposes. Part of the tumour material and macroscopically normal breast was snap-frozen in liquid nitrogen after surgery. Hematoxylin and eosin (H&E)-stained sections were prepared for assessment of the percentage of tumour cells, only samples with >70% tumour cells were selected. The normal breast tissue used for standardisation contained approximately 40% of epithelial cells. For patient characteristics see Table 1.
###end p 14
###begin p 15
Clinicopathological parameters of 170 breast cancer specimens analysed in this study.
###end p 15
###begin p 16
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 167 169 167 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
aOnly female patients with primary, unilateral, invasive breast cancer were included. bx status unknown. cAccording to TNM classification by Sobin and Wittekind [37]. d IRS= Immuno-reactive score according to Remmele and Stegner [38].
###end p 16
###begin title 17
Cell lines
###end title 17
###begin p 18
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human breast cell lines BT20, MDA-MB231, MCF7 and T47D used for this study were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured under recommended conditions.
###end p 18
###begin title 19
DNA/RNA isolation of breast cancer cells
###end title 19
###begin p 20
###xml 185 189 185 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Frozen tissue samples were dissolved in lysis buffer for subsequent DNA isolation using the blood and cell culture DNA kit (Qiagen, Hilden, Germany) or for RNA isolation by using TRIzol(R) (Gibco-BRL, Glasgow, UK) according to the protocol supplied by the manufacturer.
###end p 20
###begin title 21
Reverse Transcription PCR
###end title 21
###begin p 22
###xml 171 174 170 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(6)</sub>
###xml 228 231 226 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 333 374 331 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glyceraldehyde-3-Phosphate Dehydrogenase </italic>
###xml 375 380 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 608 612 594 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
Of the total RNA, 1 mug was reverse transcribed using the Reverse Transcription System (Promega, Madison, WI, USA). To improve transcription rate we mixed oligo-dT and pdN(6)-Primers 1:2. For PCR, 1 mul cDNA was amplified using ID4, (For 5'-CGC TCA CTG CGC TCA ACA C-3' Rev 5'-CTA ACT TCT GCT CTT CCC CC-3', product size 148 bp) and Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) (For 5'-GAA GGT GAA GGT CGG AGT CA-3' Rev 5'-TGG ACT CCA CGA CGT ACT CA-3', product size 289 bp) primers. Reactions were initiated as "Hot Start" PCR at 95degreesC for 5 min and held at 80degreesC before addition of 1 unit of Taq DNA polymerase (Roche, Mannheim, Germany). Cycle conditions applied for both genes were: 94degreesC for 5 min, 38 cycles of 95degreesC for 1 min, 58degreesC for 1 min, 72degreesC for 1 min and a final extension at 72degreesC for 10 min. PCR analyses were carried out in a PTC-200 cycler (Bio-Rad, formerly MJ Research, Hercules, CA, USA). The amplification products were analysed on a 2% agarose gel containing ethidium bromide under UV-light.
###end p 22
###begin title 23
Semi-quantitative realtime PCR
###end title 23
###begin p 24
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 255 256 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 405 411 400 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 415 419 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 506 510 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 583 584 578 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 695 701 690 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 745 747 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 847 851 842 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
Semi-quantitative PCR was performed using the LightCycler system together with the LightCycler DNA Master SYBR Green I Kit (Roche, Mannheim, Germany) as previously described [22]. Reaction volumes of 20 mul consisted of the following components: 3 mM MgCl2, 10 muM forward primer, 10 muM reverse primer, 2 mul LightCycler DNA Master SYBR Green I and 1 mul of cDNA as PCR template. For primer sequences of GAPDH and ID4 amplification, see Reverse Transcription PCR section. To assure maximum specificity of ID4 mRNA detection a touchdown PCR program was designed (see additional file 1). Gene expression was quantified by the comparative CT method, normalising CT-values to the housekeeping gene GAPDH and calculating relative expression values [23]. Post amplification melting curve analyses were performed to assure product specificity. Relative ID4 expression levels were standardised in comparison to the expression level of pooled normal breast tissue samples. To ensure experiment accuracy, all reactions were performed in triplicates.
###end p 24
###begin title 25
Bisulphite-modification and methylation-specific PCR
###end title 25
###begin p 26
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 642 646 631 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 812 816 801 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 937 941 926 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 975 977 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 710 715 <span type="species:ncbi:9606">human</span>
###xml 852 857 <span type="species:ncbi:9606">human</span>
Bisulphite-modification and methylation-specific PCR (MSP) were performed as previously described [22,24,25]. Of the genomic DNA, 1 mug was bisulphite-treated using the EZ DNA Methylation Kittrade mark (Zymo Research, Orange, CA, USA) according to the manufacturer's specifications. For MSP, 1 mul of modified DNA was amplified using MSP primers that specifically recognise the unmethylated (U For 5'-GGT AGT TG GAT TTT TTG TTT TTT AGT ATT-3' Rev 5'-AAC TAT ATT TAT AAA ACC ATA CAC CCC A-3, product size 157 bp) or methylated (M For 5'-TAG TCG GAT TTT TCG TTT TTT AGT ATC-3' Rev 5'-CTA TAT TTA TAA AAC CGT ACG CCC CG-3', product size 161 bp) ID4 promoter sequence after bisulphite conversion. DNA derived from human carcinoma cell line MDA-MB231 was bisulphite-treated to serve as a control for the unmethylated ID4 promoter sequence. DNA derived from human mammary carcinoma cell line BT20 was used as a positive control for methylated ID4 sequences as described elsewhere [20]. Amplification products were visualised by UV-illumination on 3% low range ultra agarose gel (Bio-Rad Laboratories, Hercules, CA, USA) containing ethidium bromide.
###end p 26
###begin title 27
5-aza-2'-deoxycytidine (DAC) and trichostatin A (TSA) treatment
###end title 27
###begin p 28
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Cells were plated at a density of 3 x 104 cells/cm2 in a 6-well plate on day 0. The demethylating agent DAC [26] (Sigma-Aldrich, Deisenheim, Germany) was added to a final concentration of 1 muM in fresh medium on days 1, 2 and 3. Additionally, 300 nM TSA (Sigma-Aldrich) was added on day 3. Cells were harvested on day 4 for RNA and DNA extraction. Control cells were incubated without the addition of DAC or TSA and fresh medium was supplied on days 1, 2 and 3.
###end p 28
###begin title 29
Immunhistochemistry (IHC)
###end title 29
###begin p 30
###xml 521 525 515 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 684 686 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 722 723 714 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 237 243 <span type="species:ncbi:9986">rabbit</span>
###xml 249 254 <span type="species:ncbi:9606">human</span>
Sections of three micrometers were dried for 30 min at 72degreesC, deparaffinised in xylene, rehydrated in a decreasing ethanol series and subsequently boiled for 35 min in Tris-EDTA buffer (pH 9.0) for antigen retrieval. Polyclonal ID4 rabbit anti-human antibody (Sc291, Santa Cruz, CA, USA) was utilised in 1:150 dilution and sections were incubated for 90 min. IHC was performed by using the ChemMate Envision Kit (DAKO, Hamburg, Germany). Sections were counterstained with Mayer's hematoxylin and embedded in Entellan(R) mounting medium (EMS Diatome, Fort Washington, PA, USA). Sections of normal and tumorous colon tissues were used for positive controls as described elsewhere [13] (for details, see additional file 2). The application of primary antibody to tissue sections was omitted in negative controls.
###end p 30
###begin title 31
###xml 44 51 <span type="species:ncbi:9606">patient</span>
Statistical analyses of clinicopathological patient data
###end title 31
###begin p 32
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">delta </italic>
###xml 496 500 496 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 664 668 664 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
Statistical analyses were carried out by using SPSS version 14.0 (SPSS, Chicago, IL). Differences were considered statistically significant when P-values were located below 0.05. The two-sided, non-parametric Dunn's-Multiple-Comparison-Test was used in order to compare the delta CT values of the realtime RT-PCR results of the breast cancer group with the normal breast group as well as the different methylation groups. Two-sided Log-rank tests were performed in order to correlate RFS/OS with ID4 methylation and other clinicopathological parameters. A multivariate Cox-regression analysis was performed in order to test the independent prognostic relevance of ID4 methylation. The limit for reverse selection procedures was P = 0.2. The proportionality assumption for all variables was assessed with log-negative-log survival distribution functions.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
ID4 methylation, expression and re-expression analysis of mammary cell lines
###end title 34
###begin p 35
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 218 222 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 394 398 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 649 653 649 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 794 798 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 864 868 864 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1077 1081 1077 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 460 465 <span type="species:ncbi:9606">human</span>
First, we established a methylation-specific PCR (MSP) for the ID4 gene, using MSP primers which are complementary to the central CpG island of the ID4 promoter region (Figure 1A). The designed MSP primers amplify the ID4 promoter sequence starting approximately 30 bp upstream of the transcription start site (TSS). In order to demonstrate that ID4 promoter methylation may be associated with ID4 gene silencing, we performed demethylation analyses with four human breast cancer cell lines (MDA-MB231, BT20, MCF7 and T47D). For this purpose, these cell lines were treated with the demethylating agent DAC and the histone deacetylase inhibitor TSA. ID4 expression was measured 72 h later by performing realtime PCR (Figure 1B). We found that in all methylated cell lines (BT20, MCF7, and T47D) ID4 mRNA expression was restored after the treatment. The increase of ID4 expression after promoter demethylation was 119-fold in T47D cells, 38-fold in MCF7 cells and 19-fold in BT20 breast cancer cells. The unmethylated cell line MBA-MD231 showed just a marginal alteration of its ID4 mRNA levels.
###end p 35
###begin p 36
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) Illustration of the <italic>ID4 </italic>gene promoter region and of MSP primer topology</bold>
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 519 523 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 750 759 750 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 789 793 789 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 746 840 746 840 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) <italic>In vitro </italic>demethylation analysis of the <italic>ID4 </italic>promoter in four human breast cancer cell lines</bold>
###xml 1026 1030 1026 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1117 1121 1117 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1201 1205 1201 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1255 1259 1255 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1304 1308 1304 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1300 1399 1300 1399 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) <italic>ID4 </italic>promoter methylation analysis in primary human breast cancer (n = 170) using MSP technology</bold>
###xml 810 815 <span type="species:ncbi:9606">human</span>
###xml 1349 1354 <span type="species:ncbi:9606">human</span>
###xml 1438 1446 <span type="species:ncbi:9606">patients</span>
###xml 1700 1705 <span type="species:ncbi:9606">Human</span>
(A) Illustration of the ID4 gene promoter region and of MSP primer topology. Two CpG islands are located in the ID4 promoter region upstream of the transcription start site (TSS). Methylation-specific PCR (MSP) primers used for this study were positioned within the central CpG island (-615 until +139) near the TSS, detecting an amplicon indicated by the black box. The PCR product size of the unmethylated ID4 promoter sequence is 161 bp and similar in size to the product achieved with primers indicating methylated ID4 promoters (157 bp). The primers for the U reaction cover the bases -194 until -166 and -60 until -33. The primers for the M reaction cover the bases -192 until -166 and -60 until -35. All positions are relative to the TSS. (B) In vitro demethylation analysis of the ID4 promoter in four human breast cancer cell lines. Cells were incubated with 5-aza-2'-deoxycytidine (DAC) and trichostatin A (TSA) for 72 h and 24 h, respectively. For each cell line, the methylation status and the fold change (FC) of ID4 mRNA re-expression are shown. All methylated cell lines (BT20, MCF7 and T47D) restored ID4 expression after demethylating treatment. MDA-MB231 remains unmethylated in the ID4 promoter and exhibits only a marginal increase of ID4 mRNA expression after DAC/TSA treatment. (C) ID4 promoter methylation analysis in primary human breast cancer (n = 170) using MSP technology. MSP results from nine representative patients (#) are shown. DNA bands in lanes labelled with U indicate PCR products amplified with primers recognising the unmethylated promoter sequence. DNA bands in lanes labelled with M represent products amplified with primers specific for methylated alleles. Human breast cancer cell lines BT20 and MDA-MB321 were used as positive controls for methylated and unmethylated ID4 promoter sequences, as described previously [20]. Water was used as non template control (NTC).
###end p 36
###begin title 37
###xml 36 41 <span type="species:ncbi:9606">human</span>
ID4 promoter methylation in primary human breast cancer
###end title 37
###begin p 38
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 409 413 409 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 90 95 <span type="species:ncbi:9606">human</span>
###xml 257 262 <span type="species:ncbi:9606">human</span>
###xml 457 462 <span type="species:ncbi:9606">human</span>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
Recently we have demonstrated that ID4 mRNA expression is downregulated in 78% (39/50) of human primary breast carcinomas [27]. Umetani et al. had shown before that promoter hypermethylation is implicated to be an effective mechanism of ID4 inactivation in human breast cancer, albeit this group only analysed small sized (T1) breast tumours [20]. In order to determine the exact methylation frequency of the ID4 promoter in a clinical relevant spectrum of human breast cancer we analysed genomic DNA from 170 primary breast cancer patients by MSP technology.
###end p 38
###begin p 39
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 210 214 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
Representative results are shown in Figure 1C. In total ID4 promoter methylation was found in 68.9% (117/170) of breast cancer specimens. Accordingly, 31.1% of the breast cancer specimens (53/170) exhibited no ID4 promoter methylation. Normal breast tissues (n = 13) were analysed by MSP as well and did not exhibit any ID4 promoter methylation (data not shown), indicating that this is a tumour-specific process.
###end p 39
###begin title 40
###xml 76 81 <span type="species:ncbi:9606">human</span>
Correlation analyses between ID4 promoter methylation and ID4 expression in human breast cancer
###end title 40
###begin p 41
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 394 398 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 594 598 594 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 677 681 677 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 721 725 721 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 759 763 759 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1028 1032 1028 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1173 1181 1173 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A, B, C</xref>
###xml 1230 1234 1230 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1291 1295 1291 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1501 1505 1501 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1632 1636 1632 1636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1760 1765 1760 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B, C</xref>
Next, we wanted to analyse whether ID4 promoter methylation consequently led to silencing of the ID4 promoter as measured by realtime PCR analysis of the gene transcript. For this purpose, a part of the same breast cancer cohort (n = 46) used previously for methylation analysis was re-assessed (Figure 2A). Compared to a normal breast tissue standard (12 pooled normal breast tissues) loss of ID4 mRNA expression in unmethylated breast cancer specimens was marginal (median fold change = 1.3). In contrast, methylated breast cancer specimens exhibited a highly significant (P < 0.001) loss of ID4 expression (median fold change = 12.3). Thus, these data clearly indicate that ID4 promoter methylation is associated with ID4 gene silencing. The comparison of ID4 expression in breast tumours versus normal breast tissues resulted in 82.6% downregulation in tumour samples by the fold change two (FC 2) approach. In order to confirm that promoter methylation also affects loss of ID4 protein, we performed a parallel analysis of ID4 promoter methylation, mRNA and protein expression in three matched samples with normal breast tissue and corresponding tumour tissue (Figure 3A, B, C). Breast cancer specimens (T) with unmethylated ID4 promoter exhibited only a marginal decline (FC = 1.1) in ID4 mRNA expression. In accordance with the mRNA data, the abundance of ID4 protein in the tumour was very similar to that found in the corresponding normal tissue (N). Breast cancer specimens exhibited strong ID4 mRNA downregulation (16-fold and 71-fold, respectively) in comparison to their corresponding normal tissues depending on clear ID4 promoter methylation. Note, that in these tumour tissues nearly complete loss of ID4 protein expression was evident (Figure 3B, C).
###end p 41
###begin p 42
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) Correlation between <italic>ID4 </italic>expression and <italic>ID4 </italic>promoter methylation in human breast cancer</bold>
###xml 135 139 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 257 261 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 607 611 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 826 830 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 741 850 741 850 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) Kaplan-Meier analysis of patients' recurrence-free survival (RFS) in relation to <italic>ID4 </italic>promoter methylation</bold>
###xml 994 998 994 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1058 1061 1058 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4</italic>
###xml 1252 1256 1252 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 71 76 <span type="species:ncbi:9606">human</span>
###xml 201 206 <span type="species:ncbi:9606">human</span>
###xml 770 778 <span type="species:ncbi:9606">patients</span>
###xml 931 939 <span type="species:ncbi:9606">patients</span>
###xml 1035 1043 <span type="species:ncbi:9606">Patients</span>
###xml 1235 1243 <span type="species:ncbi:9606">patients</span>
(A) Correlation between ID4 expression and ID4 promoter methylation in human breast cancer. Box plot analysis illustrating the loss of ID4 expression in relation to ID4 promoter methylation in primary human breast cancer. The Y axis indicates the factor of ID4 mRNA downregulation in breast cancer specimens (n = 46) relative to a normal breast standard (a pool of 12 normal breast tissue samples) as the fold change (FC) N/T. Unmethylated tumours exhibited ID4 expression (median FC = 1.3) very similar to normal breast cells. In contrast, methylated breast cancer specimens displayed an increased loss of ID4 expression (median FC = 12.3). Horizontal lines: group medians; boxes: 25-75% quartiles; vertical lines: range, peak and minimum. (B) Kaplan-Meier analysis of patients' recurrence-free survival (RFS) in relation to ID4 promoter methylation. Distribution of time (months) and tumour-related death among 115 breast cancer patients with positive (lower graph) or negative (upper graph) ID4 promoter methylation state is shown. Patients harbouring an ID4-methylated tumour have an estimated mean RFS time of 80 months (95% confidence interval: 67-93 months) compared with 101 months (95% confidence interval: 87-115 months) for patients without ID4 tumour methylation. See text for details.
###end p 42
###begin p 43
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Correlation of <italic>ID4 </italic>promoter methylation with ID4 expression on both mRNA and protein level</bold>
###xml 105 109 105 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 391 395 391 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 704 708 704 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 857 861 857 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
Correlation of ID4 promoter methylation with ID4 expression on both mRNA and protein level. Coherence of ID4 promoter methylation and ID4 expression in three representative samples of primary breast cancer and corresponding normal tissue (matched pairs a, b, c). Normal tissues are labelled with N. Their corresponding tumours are labelled with T. For each sample, ID4 promoter methylation, ID4 mRNA expression and ID4 immunohistochemical staining are shown (original magnification: 400x). The Fold change (FC) of ID4 mRNA downregulation is calculated by the expression ratio of normal (N) and tumourous tissue (T) for each matched pair (a, b, c). Matched pair a: Unmethylated tumour showed very similar ID4 mRNA and protein expression compared to the corresponding normal breast tissue. Matched pairs b and c: Methylated tumours exhibited explicit loss of ID4 mRNA and ID4 protein in comparison to the corresponding normal breast tissues (N). See text for details.
###end p 43
###begin title 44
###xml 44 51 <span type="species:ncbi:9606">patient</span>
###xml 61 68 <span type="species:ncbi:9606">patient</span>
Statistical analysis of clinicopathological patient data and patient survival
###end title 44
###begin p 45
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 m</italic>
###xml 512 516 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 636 640 636 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 707 711 707 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 795 799 795 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 905 909 905 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1043 1047 1043 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1127 1131 1127 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 120 127 <span type="species:ncbi:9606">patient</span>
###xml 622 630 <span type="species:ncbi:9606">patients</span>
###xml 685 693 <span type="species:ncbi:9606">patients</span>
###xml 888 896 <span type="species:ncbi:9606">patients</span>
Finally, descriptive Fisher's exact tests were performed in order to correlate ID4 methylation with clinicopathological patient characteristics (Table 2). A hypermethylated ID4 promoter was significantly associated with positive lymph node status (P = 0.03) and loss of ID4 mRNA expression (P < 0.001). No associations were found with age at diagnosis, tumour size, histological grade/type and oestrogen/progesterone receptor status. A comparison between recurrence-free survival (RFS)/overall survival (OS) and ID4 methylation status is shown in Table 3. We found an increased risk for tumour recurrence in breast cancer patients with ID4 promoter methylation (P = 0.036) compared to patients with lack of ID4 methylation (Figure 2B). Estimation was accomplished by the method of Kaplan-Meier. ID4 promoter methylation is considerably associated with a low 10-years RFS rate (47%) while patients without ID4 promoter methylation have a 10-years RFS rate of 71%. Cox regression models including factors possibly influencing RFS in relation to ID4 promoter methylation, failed significance in confirming the prognostic value of ID4 promoter methylation as an independent marker, probably due to its close relation to positive lymph node status (data not shown).
###end p 45
###begin p 46
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
Clinicopathological parameters in relation to ID4 promoter methylation
###end p 46
###begin p 47
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 196 198 196 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
a Only female patients with primary, unilateral, invasive breast cancer were included. Significant P- values are marked in bold face. bAccording to TNM classification by Sobin and Wittekind [37]. c IRS = Immuno-reactive score according to Remmele and Stegner [38]. dFisher's exact test. Significant P- values are marked in bold face.
###end p 47
###begin p 48
Univariate analysis of clinicopathological parameters influencing recurrence-free survival (RFS) and overall survival (OS)
###end p 48
###begin p 49
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 148 150 148 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 217 218 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
aOnly female patients with primary, unilateral, invasive breast cancer were included. bAccording to TNM classification by Sobin and Wittekind [37]. c IRS = Immuno-reactive score according to Remmele and Stegner [38]. dFisher's exact test. Significant P-values are marked in bold face.
###end p 49
###begin title 50
Discussion
###end title 50
###begin p 51
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 387 392 <span type="species:ncbi:9606">human</span>
Previous studies have shown that the HLH transcription factor ID4 is functionally associated with fundamental processes such as differentiation, proliferation, apoptosis and angiogenesis [3] via interaction with cell cycle factors like RB1-protein or the PAX-proteins [28]. For this reason it is not surprising that all ID family members have been reported to be dysregulated in several human tumour entities [29].
###end p 51
###begin p 52
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 245 249 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 472 476 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 605 609 605 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 656 660 656 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 712 721 712 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 819 823 819 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 933 937 933 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1017 1021 1017 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1117 1119 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1242 1246 1242 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1288 1292 1288 1292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1377 1381 1377 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1494 1498 1494 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1596 1600 1596 1600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1655 1659 1655 1659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1705 1709 1705 1709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1778 1780 1778 1780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1847 1851 1847 1851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1911 1913 1911 1913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 96 101 <span type="species:ncbi:9606">human</span>
###xml 530 535 <span type="species:ncbi:9606">human</span>
###xml 587 592 <span type="species:ncbi:9606">human</span>
###xml 678 683 <span type="species:ncbi:9606">human</span>
###xml 961 966 <span type="species:ncbi:9606">human</span>
###xml 1175 1180 <span type="species:ncbi:9606">human</span>
###xml 1316 1321 <span type="species:ncbi:9606">human</span>
###xml 1522 1527 <span type="species:ncbi:9606">human</span>
###xml 1615 1620 <span type="species:ncbi:9606">human</span>
###xml 1883 1886 <span type="species:ncbi:10116">rat</span>
###xml 1977 1982 <span type="species:ncbi:9606">human</span>
###xml 1987 1990 <span type="species:ncbi:10116">rat</span>
Epigenetic inactivation of the ID4 gene through promoter methylation has been shown for several human tumour types such as gastric carcinoma [12], colorectal carcinoma [13] and acute leukaemia [14]. In breast cancer the epigenetic regulation of ID4 expression was demonstrated in 67% (16/24) of node positive tumours, although only breast tumours of small size (T1 tumours) were analysed in this study [20]. Thus, it was the aim of the present work to analyse the role of ID4 promoter methylation in a clinical relevant cohort of human breast cancer and further to study this process in human cell lines. ID4 promoter methylation is indeed associated with ID4 gene silencing in human breast cancer cell lines as in vitro demethylation experiments with DAC in three methylated breast cancer cell lines restored abundant ID4 mRNA expression. These cell line results represent the prerequisite for a putative tumour suppressive role of ID4 promoter methylation in human breast cancer. Up to now, epigenetic silencing of ID4 has been demonstrated only for gastric adenocarcinoma [12] and colorectal carcinoma cell lines [13]. In addition, we could show that a high percentage of human primary breast cancers (69%) exhibit hypermethylation of the ID4 promoter. Furthermore, we could show that ID4 promoter methylation in human breast cancer is significantly associated with loss of ID4 mRNA expression, this tight correlation again being a prerequisite for a putative tumour suppressive function of ID4 promoter methylation in human breast cancer. Our results demonstrate a highly significant loss of ID4 mRNA in 83% of human breast cancers. This incidence of ID4 expression loss is very similar to the 78% of ID4 mRNA downregulation measured previously by a cancer profiling array [27]. However, our findings are not in accordance with the determined ID4 mRNA upregulation described for rat breast carcinoma cells [19]. Further studies will have to show, whether ID4 regulation in human and rat breast carcinogenesis might differ.
###end p 52
###begin p 53
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 327 331 327 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 962 964 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 999 1003 999 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1167 1171 1167 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1207 1211 1207 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 1534 1536 1534 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1565 1567 1565 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 235 243 <span type="species:ncbi:9606">patients</span>
###xml 383 388 <span type="species:ncbi:9606">human</span>
###xml 511 516 <span type="species:ncbi:9606">human</span>
###xml 612 617 <span type="species:ncbi:9606">human</span>
###xml 855 863 <span type="species:ncbi:9606">patients</span>
###xml 1240 1245 <span type="species:ncbi:9606">human</span>
###xml 1419 1424 <span type="species:ncbi:9606">human</span>
Statistical analysis furthermore revealed that ID4 promoter methylation represents an adverse prognostic factor. Breast cancer patients harbouring a methylated ID4 promoter were found to have a decreased mean RFS time in comparison to patients without ID4 methylation in the tumour, supporting the hypothesis that a functional ID4 gene indeed confers tumour suppressive functions to human breast tissue. Thus, ID4 may have the opposite function of ID1 and ID2, which are thought to have oncogenic properties in human breast cancer cells [30,31]. Additionally, Perk et al. reported an increased ID1 expression in human bladder and prostate cancer [32]. Supporting a metastasis suppressing function of ID4, we found a significant positive correlation between ID4 promoter methylation and lymph node metastasis in our large cohort (n = 170) of breast cancer patients. This correlation was also suggested for the cohort of T1 tumours in the study of Umetani et al. [20]. No further correlations between ID4 methylation and other clinicopathological parameters were found. To our knowledge, this is the first study presenting a distinct loss of ID4 protein expression and ID4 mRNA downregulation associated with ID4 promoter hypermethylation in human breast cancer. The loss of protein expression, which modulates the activity of its downstream targets, is an important milestone for the validation of ID4 as a novel TSG in human breast cancer. Up to now loss of the ID4 protein expression was observed in sporadic breast adenocarcinomas [33] and colorectal carcinomas [13].
###end p 53
###begin p 54
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 450 455 <span type="species:ncbi:9606">human</span>
###xml 605 610 <span type="species:ncbi:9606">human</span>
However, in these studies correlations between ID4 methylation and ID4 transcription were not determined. In conclusion, our data show that ID4 is a potential tumour suppressor gene in breast cancer that becomes epigenetically inactivated during cancer development owing to aberrant promoter methylation. Our investigations form a basis for further functional analyses in order to light up the importance of ID4 for the progression and metastasis of human breast cancer. The inactivation of tumour suppressor genes through promoter methylation offers new opportunities to identify novel DNA biomarkers in human cancer diseases that may also represent targets for improved future therapies [34,35]. DNA methylation marker panels promise early detection, risk assessment, chemoprediction and monitoring for disease recurrence in combination with a minimally/non-invasive detection in the blood stream or from archived tissue specimens [36].
###end p 54
###begin title 55
Conclusion
###end title 55
###begin p 56
###xml 409 414 <span type="species:ncbi:9606">human</span>
In summary, our analyses regarding aberrant ID4 promoter methylation and differential ID4 expression on both mRNA and protein level lead to the following conclusions: ID4 is indeed a tumour suppressor gene in normal breast tissue, which undergoes epigenetical silencing during breast tumour development. The methylation status of ID4 predicts early tumour relapse and could serve as a prognostic biomarker in human breast cancer.
###end p 56
###begin title 57
Competing interests
###end title 57
###begin p 58
The authors declare that they have no competing interests.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
###xml 314 321 <span type="species:ncbi:9606">patient</span>
###xml 411 418 <span type="species:ncbi:9606">patient</span>
###xml 508 515 <span type="species:ncbi:9606">patient</span>
EN participated in the design of the study, carried out the experimental data acquisition, performed data analyses/interpretation and drafted the manuscript. JV processed clinical samples for realtime PCR and MSP analyses, participated in the design of the study and critically revised the manuscript. DN provided patient material and clinicopathological data and critically revised the manuscript. FH provided patient material and clinicopathological data and critically revised the manuscript. AH provided patient material and clinicopathological data and critically revised the manuscript. OG participated in the design of MSP analyses and critically revised the manuscript. RK participated in the design and coordination of the study, supplied administrative support and critically revised the manuscript. ED designed and coordinated the study and critically revised the manuscript. All authors read and approved the final manuscript.
###end p 60
###begin title 61
Pre-publication history
###end title 61
###begin p 62
The pre-publication history for this paper can be accessed here:
###end p 62
###begin p 63

###end p 63
###begin title 64
Supplementary Material
###end title 64
###begin title 65
Additional file 1
###end title 65
###begin p 66
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID4 </italic>
"Touchdown PCR for ID4 mRNA expression analysis"
###end p 66
###begin p 67
Click here for file
###end p 67
###begin title 68
Additional file 2
###end title 68
###begin p 69
###xml 0 137 0 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">"Positive controls for the immunohistochemical staining with normal and tumourous colon tissues for a polyclonal ID4 antibody (sc-491)." </bold>
"Positive controls for the immunohistochemical staining with normal and tumourous colon tissues for a polyclonal ID4 antibody (sc-491)." A) and C) are negative controls without ID4 antibody incubation for normal and tumourous colon tissues, respectively. B) Intensive cytoplasmatic staining of a normal colon tissue. D) Negative ID4 protein staining for an infiltrating colon carcinoma (G2, pT2, pN0, pMx).
###end p 69
###begin p 70
Click here for file
###end p 70
###begin title 71
Acknowledgements
###end title 71
###begin p 72
###xml 415 422 <span type="species:ncbi:9606">patient</span>
###xml 501 506 <span type="species:ncbi:9606">Human</span>
We thank Sonja von Serenyi, Sevim Alkaya and Inge Losen for excellent technical assistance and Monika Klinkhammer-Schalke and Armin Pauer from the Tumour Registry Regensburg for continuous help in obtaining clinical follow-up data. We would like to thank Dr. Nuran Bektas for evaluating the tissue sections. We are thankful to Prof. Matthias Durst (Friedrich-Schiller University Jena, Germany) for kindly providing patient samples and follow-up data. This work is a research project within the German Human Genome Project and has been supported by the BMBF Grants 01KW0401 to ED.
###end p 72
###begin article-title 73
Id proteins in cell cycle control and cellular senescence
###end article-title 73
###begin article-title 74
###xml 80 85 <span type="species:ncbi:9606">human</span>
Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells
###end article-title 74
###begin article-title 75
Helix-loop-helix proteins in mammary gland development and breast cancer
###end article-title 75
###begin article-title 76
###xml 53 58 <span type="species:ncbi:9606">human</span>
The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer
###end article-title 76
###begin article-title 77
Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index
###end article-title 77
###begin article-title 78
Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas
###end article-title 78
###begin article-title 79
Study of gene expression in thyrotropin-stimulated thyroid cells by cDNA expression array: ID3 transcription modulating factor as an early response protein and tumor marker in thyroid carcinomas
###end article-title 79
###begin article-title 80
Id proteins at the cross-road of development and cancer
###end article-title 80
###begin article-title 81
The epigenomics of cancer
###end article-title 81
###begin article-title 82
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
###end article-title 82
###begin article-title 83
DNA methylation in breast cancer
###end article-title 83
###begin article-title 84
Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma
###end article-title 84
###begin article-title 85
Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis
###end article-title 85
###begin article-title 86
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia
###end article-title 86
###begin article-title 87
###xml 75 80 <span type="species:ncbi:9606">human</span>
Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma
###end article-title 87
###begin article-title 88
BRCA1 dysfunction in sporadic basal-like breast cancer
###end article-title 88
###begin article-title 89
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach
###end article-title 89
###begin article-title 90
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer
###end article-title 90
###begin article-title 91
###xml 89 92 <span type="species:ncbi:10116">rat</span>
Id4 regulates mammary epithelial cell growth and differentiation and is overexpressed in rat mammary gland carcinomas
###end article-title 91
###begin article-title 92
Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer
###end article-title 92
###begin article-title 93
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
###end article-title 93
###begin article-title 94
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis
###end article-title 94
###begin article-title 95
Real-time quantitative RT-PCR after laser-assisted cell picking
###end article-title 95
###begin article-title 96
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 96
###begin article-title 97
High sensitivity mapping of methylated cytosines
###end article-title 97
###begin article-title 98
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
###end article-title 98
###begin article-title 99
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer
###end article-title 99
###begin article-title 100
Role of Id family proteins in growth control
###end article-title 100
###begin article-title 101
ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis
###end article-title 101
###begin article-title 102
###xml 76 81 <span type="species:ncbi:9606">human</span>
A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells
###end article-title 102
###begin article-title 103
Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells
###end article-title 103
###begin article-title 104
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 108 114 <span type="species:ncbi:9986">rabbit</span>
Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody
###end article-title 104
###begin article-title 105
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis
###end article-title 105
###begin article-title 106
###xml 78 83 <span type="species:ncbi:9606">human</span>
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours
###end article-title 106
###begin article-title 107
DNA methylation in breast cancer
###end article-title 107
###begin article-title 108
The power and the promise of DNA methylation markers
###end article-title 108
###begin article-title 109
[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]
###end article-title 109

